Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821327 · ClinicalTrials.gov registry record · Phase 2
Gemzar, Cisp, Sunitinib Urothelial Ca
A Phase 2 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00821327 is a Phase 2 study that has completed, run by US Oncology Research. The registered enrollment target is 36 participants.
The verdict
NCT00821327, a Phase 2 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary objective of this nonrandomized Phase II study is to evaluate the objective response rate (ORR, CR+PR) in patients with advanced/metastatic UC treated with the combination of gemcitabine, cisplatin, and sunitinib.
Interventions
- DRUG Gemcitabine, Cisplatin, Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00821327
The ClinicalTrials.gov registry entry for NCT00821327 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, Cisplatin, Sunitinib is the first listed.
NCT00821327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00821327 about?
NCT00821327 is a clinical study titled "Gemzar, Cisp, Sunitinib Urothelial Ca". The primary objective of this nonrandomized Phase II study is to evaluate the objective response rate (ORR, CR+PR) in patients with advanced/metastatic UC treated with the combination of gemcitabine, cisplatin, and sunitinib.
What is the current status of trial NCT00821327?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2008-08. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00821327?
The interventions under investigation include: Gemcitabine, Cisplatin, Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00821327?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.